
June 2 (Reuters) - Sanofi SASY.PA:
PRESS RELEASE: SANOFI TO ACQUIRE BLUEPRINT MEDICINES, EXPANDING PORTFOLIO IN RARE IMMUNOLOGICAL DISEASE AND ADDING EARLY-STAGE PIPELINE IN IMMUNOLOGY
SANOFI TO FINANCE DEAL WITH CASH AND NEW DEBT
SANOFI EXPECTS TO COMPLETE ACQUISITION IN Q3 2025
WILL PAY $129.00 PER SHARE IN CASH AT CLOSING, REPRESENTING AN EQUITY VALUE OF APPROXIMATELY $9.1 BILLION FOR BLUEPRINT
ACQUISITION IMMEDIATELY ACCRETIVE TO GROSS MARGIN
BLUEPRINT SHAREHOLDERS WILL RECEIVE ONE NON-TRADEABLE CONTINGENT VALUE RIGHT (CVR) WHICH WILL ENTITLE HOLDER TO RECEIVE TWO POTENTIAL MILESTONE PAYMENTS OF $2 AND $4 PER CVR FOR ACHIEVEMENT, RESPECTIVELY, OF FUTURE DEVELOPMENT AND REGULATORY MILESTONES FOR BLU-808
TOTAL EQUITY VALUE OF BLUEPRINT TRANSACTION, INCLUDING POTENTIAL CVR PAYMENTS, REPRESENTS APPROXIMATELY $9.5 BILLION ON A FULLY DILUTED BASIS
Further company coverage: SASY.PA